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ABSTRACT
Objective: The study’s purpose has been to describe the sociodemographic and clinical profile of elderly chronic 
omeprazole users. Methods: This is a cross-sectional study. The participants were patients within the age group 
over 60 years old, who used omeprazole from the Public Pharmacy located in Panambi city, Rio Grande do 
Sul State. Results: A total of 60 elderly chronic omeprazole users participated in the study with an average of 
67.90 ± 5.6 years old. Two serious drug interactions were identified involving citalopram and clopidogrel. It 
was found in some prescriptions the presence of drugs that have their absorption altered by concomitant use 
of omeprazole, such as captopril (25%) and enalapril (16.7%). Conclusion: Based on the findings, it is possible 
to highlight that this particular population is susceptible to risks that needs pharmaceutical follow-up.
Descriptors: Antiulcer, elderly, omeprazole.
RESUMO
Objetivo: Descrever o perfil sociodemográfico e clínico de idosos usuários crônicos de omeprazol. Método: Trata-se de um estudo 
transversal com usuários com idade superior a 60 anos, que retiraram o omeprazol na Farmácia Pública de Panambi/RS. Resultados: 
Participaram da pesquisa sessenta idosos, com idade média de 67,90 ±5,6 anos. Duas interações graves foram identificadas envolvendo 
citalopram e clopidogrel. Observou-se a presença nas prescrições de medicamentos que tem a sua absorção alterada pelo uso concomitante 
com o omeprazol como captopril (25%) e enalapril (16,7%). Conclusão: Dessa forma, evidenciou-se uma população suscetível a riscos que 
necessita de acompanhamento farmacêutico.
Descritores: Antiulcerosos, Idosos, Omeprazol
1 Pharmacy Graduate by the Universidade Regional do Noroeste do Estado do Rio Grande do Sul (UNIJUÍ), Brazil.
2 Pharmacy Graduate by the Universidade Regional do Noroeste do Estado do Rio Grande do Sul (UNIJUÍ), Pharmacist at Prefeitura 
Municipal de Ijuí.
3 Pharmacy Graduate by the Universidade Federal de Santa Maria (UFSM), MSc in Biochemistry by the Universidade Federal do Rio 
Grande do Sul (UFRGS), Assistant Professor of the Life Sciences Department at Universidade Regional do Noroeste do Estado do 
Rio Grande do Sul (UNIJUÍ), Brazil.
4 Pharmacy Graduate by the Universidade Regional do Noroeste do Estado do Rio Grande do Sul (UNIJUÍ), PhD in Pharmaceutical 
Sciences by the Universidade Federal do Rio Grande do Sul (UFRGS), Adjunct Professor of the Life Science Department at UNIJUÍ.
DOI: 10.9789/2175-5361.2019.v11i4.900-907
Sociodemographic and clinical profile of elderly people chronic...
ISSN 2175-5361
Camile L, Aline S, Karla RO, Christiane FC
901J. res.: fundam. care. online 2019 abr/jun 11(4): 900-907
RESUMÉN
Objetivo: Describir el perfil sociodemográfico y clínico de los ancianos 
usuarios crónicos de omeprazol. Método: Es un estudio transversal 
descriptivo cuantitativo. Participaron en el estudio pacientes con edad 
igual o mayor de 60 años, usuarios crónicos de omeprazol, y que acudieron 
al medicamento en la Farmacia Publica de la cuidad de Panambi/RS. 
Resultados: Participaron de la investigación 60 ancianos 51,7% del sexo 
femenino, con edad media de 67,90 ±5,6 años, 81,7% relataran alguna 
comorbilidad, siendo la más prevalente la hipertensión arterial sistémica 
(61,7%). Los medicamentos que actúan en el tracto alimentar y metabólico 
fueron los más frecuentes. Se identificaron dos graves interacciones 
relacionado al citalopram (8,4%) y clopidogrel (1,7%). Se observó en las 
prescripciones la presencia de medicamentos cuya absorción es alterada 
por el uso concomitante con el omeprazol, como el captopril (25%) y 
enalapril (16,7%). Conclusión: De esta forma, se ha evidenciado una 
populación susceptible a los riesgos y que necesita de acompañamiento 
farmacéutico.
Descriptores: Antiulceroso, Anciano, Omeprazol.
INTRODUCTION
The increase in the elderly population in Brazil is 
bringing increasing challenges to health services and 
professionals,1 evidencing the need for changes in the model 
of health care in the country.2 Population aging causes a 
greater demand for health services and, consequently, by 
drug therapy, increasing the occurrence of polypharmacy, 
which may be associated with the indiscriminate use 
of medications, and contribute to drug interactions, 
compromising treatment efficacy and patient safety.3
Antiulcer medications are often used among elderly 
people, and a Saatkamp4 study highlighted the omeprazole 
use. This substance is a Proton-Pump Inhibitor (PPI) that 
suppresses gastric acid secretion by specific inhibition 
of the H+/K+-ATPase enzyme on the secretory surface 
of the gastric parietal cell and its metabolization mainly 
occurs via the CYP2C19 isoform of the hepatic P450. This 
drug is indicated for the treatment of peptic ulcer, reflux 
esophagitis and as a component of therapy in Helicobacter 
pylori infection.5
Omeprazole was the fourth medication most used 
by elderly people attending the public health network in 
Santa Rosa city, Rio Grande do Sul (RS) State, over 2006.6 
Another study found that the drug was among the five most 
marketed in the popular pharmacy located in Ijuí city/RS.7
The use of omeprazole is safe when according to the 
medical recommendation, however, prolonged treatment 
may lead to loss of gastric acidity, which may decrease the 
absorption of vitamin B12, as well as affect the bioavailability 
of some drugs. This medicinal product, when administered, 
decreases up to 95% the production of acid in the stomach, 
increasing the pH of the medium5 and the decrease in 
acidity may impair the absorption of other medicinal 
products in concomitant use.
According to the National Therapeutic Form (NTF), 
omeprazole interacts with benzodiazepine medications, 
carbamazepine, digoxin, methotrexate increasing the 
risk of toxicity; and also with Hypericum perforatum and 
Ginkgo biloba decreasing the efficacy of omeprazole, 
and with warfarin increasing the drug anticoagulant 
effect.8 Furthermore, one study found that omeprazole, 
when administered, is able to significantly decrease bone 
mineral density once that some salts, such as calcium, 
are insoluble at basic pH and therefore less absorbable.9 
Another study suggests that the use of omeprazole tends 
to decrease bone resorption and prevent progression to 
osteopenia, so prolonged use of this drug may be related 
to bone demineralization and the risk of fractures.10
As a result, the American Society of Geriatrics updated 
Beers’ criteria, which identified potentially inappropriate 
medications for elderly use. In the new list of drugs, PPIs 
are included as potentially inappropriate for elderly people 
due to the risk of bone loss, fractures, and infection by 
Clostridium difficile.11 Up to now, no studies have been 
conducted addressing the Beers issue regarding the use 
of omeprazole by elderly people.
Given the aforementioned, the study’s goal was to 
describe the sociodemographic and clinical profile of 
elderly chronic omeprazole users.
METHODS
It is a cross-sectional and descriptive study with a 
quantitative approach. The participants were patients within 
the age group over 60 years old, who used omeprazole 
from the Public Pharmacy located in Panambi city, Rio 
Grande do Sul State, and over the period from June to 
August 2016. The sample was of the intentional type, and 
omeprazole users were identified through the prescriptions 
containing the study drug at the time it was dispensed at 
the Public Pharmacy. The interviewees were invited to 
spontaneously participate in the research and to sign the 
Free and Informed Consent Term.
The study inclusion criteria were as follows: being aged 
over 60 years old; continued use of omeprazole for at least 
six months; being able to understand, verbalize and respond 
to questions; and agree to participate in the survey.
The data were evaluated through simple descriptive 
analysis with mean and standard deviation, with the aid 
of Statistical Package for Social Science (SPSS) software 
version 20.0. The pharmacological classification of the drugs 
was performed according to the Anatomical Therapeutic 
Chemical (ATC)12 from the WHO Collaborating Center 
for Drug Statistics Methodology. Specific drug interactions 
were analyzed in the Micromedex database.13 Moreover, 
the pKa value search was performed through the Drug 
Information System,14 Drugbank.15
This study was approved by the Research Ethics 
Committee from the Universidade Regional do Noroeste 
do Estado do Rio Grande do Sul (UNIJUÍ), under the Legal 
Opinion No. 1.587.720, and Certificado de Apresentação 
para Apreciação Ética (CAAE) [Certificate of Presentation 
for Ethical Appreciation] No. 55931116.2.0000.5350.
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RESULTS
The sample consisted of 60 chronic omeprazole users, 
of whom 51.7% were female. The age ranged from 60 to 82 
years old, with a average of 67.90 ± 5.6 years old (Table 1). 
Table 1 - Sociodemographic data of the elderly patients 
under chronic use of omeprazole from the public system 
in Panambi city, Rio Grande do Sul State.n=60. 2016.
Description n %
Gender
Female 31 51.7
Male 29 48.3
Age
60 to 70 years old 43 71.7
71 to 80 years old 14 23.3
More than 80 years old 3 5
Ethnicity
White 57 95
Brown/Black 3 5
Schooling
Elementary school 57 95
High school 3 5
Marital status
Married/companion 45 75
Divorced 8 13.3
Widowed 5 8.3
Single 2 3.3
Profession
Retired 42 70
Housekeeper 11 18.3
Farmer 6 10
Driver 1 1.7
With whom do you live 
Companion/family members 50 83.3
Alone 10 16.7
Considering the interviewees, the majority were white 
(95%) and with elementary school education (95%). The 
most frequent marital situation was married/companion 
(75%), followed by divorced (13.3%). The majority of 
respondents reported being retired (70%) and living with 
relatives (83.3%) according to Table 1.
Pondering about the chronic omeprazole users 
interviewed, 81.7% reported some comorbidities, the most 
prevalent being Systemic Arterial Hypertension (SAH) 
(61.7%), followed by dyslipidemia according to Table 2. 
Table 2 - Clinical data of the elderly patients under 
chronic use of omeprazole from the public system in 
Panambi city, Rio Grande do Sul State. n=60. 2016. 
Description n %
Do you have any comorbidity?
Yes 49 81.7
No 11 18.3
Concomitant diseases
Systemic Arterial 
Hypertension
37 61.7
Dyslipidemia 24 40
Description n %
Type 2 Diabetes Mellitus 19 31.7
Cardiopathy 12 20
Hepatopathy 2 3.3
Using purpose (self-reported)
Gastritis 22 36.6
Heartburn 21 35
Reflux esophagitis 16 26.7
Stomach ulcer 1 1.7
Do you have dyspeptic symptoms?
Yes 32 53.3
No 26 43.3
Did not answer 2 3.4
Omeprazole daily dose
20 mg 51 85
40 mg 9 15
For how long have you been taking omeprazole?
1 to 5 years 30 50
6 to 10 years 22 36.7
More than 10 years 5 8.3
Less than 1 year 3 5
When do you take omeprazole?
Morning 52 86.7
Night 2 3.3
Did not answer 6 10
Did you feel any side effect during the omeprazole use?
No 58 96.7
Yes 2 3.3
For all the interviewees of this study, the physician 
indicated the use of omeprazole and the most commonly 
reported purposes were gastritis (36.6%), heartburn 
(35%) and reflux oesophagitis (26.7), and a large part of 
omeprazole users reported dyspeptic symptoms (53.3%) 
and none reported Helicobacter pylori infection.
The daily dose of 20 mg was the most evidenced among 
the respondents, corresponding to 85% of these. Half of 
the interviewees used omeprazole for less than five years, 
and five patients have been using it for more than 10 
years, as seen in Table 2. Considering those interviewed, 
nine (15%) use calcium concurrently with omeprazole. 
Furthermore, the most cited interviewee was the morning, 
corresponding to 86.7% (Table 2).
When asked about the side effects related to omeprazole, 
96.7% answered that they did not feel any alteration with the 
use of this medication, only two (3.3%) interviewed reported 
headaches, 18.3% of patients used other medications for 
the stomach, and of these, 11.7% reported using Olina® 
and 6.6% Leite de Magnésia®.
The majority (51.7%) reported using the drug every 
day and 48.3% reported forgetting a few times during 
the week. When questioned about what they do when 
they forget to administer the medicine, 33.3% say they no 
longer use that day and 15% administer at the time they 
remember. When the drug is missing in the public network, 
40% of respondents reported purchasing at commercial 
pharmacies (Table 2).
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Of the chronic users of omeprazole, 30% use 5 or more 
medications concomitantly. And only one claimed to use 
this drug for the purpose of protecting the gastric tract.
According to Table 3, most elderly chronic users of 
omeprazole take drugs that act on the gastrointestinal tract 
and metabolism, followed by the cardiovascular system. 
Simvastatin (40%) and captopril (25%) were the most 
commonly used drugs in the study participants.
Table 3 - Medications sorted according to the Anatomical 
Therapeutic Chemical (ATC) in first level and being taken 
by patients under chronic use of omeprazole from the 
public system in Panambi city, Rio Grande do Sul State. 
n=60. 2016. 
Medicines n %
Gastrointestinal tract and metabolism (A) 101 45.09
Omeprazole 60 100
Metformin 14 23.3
Acetylsalicylic acid 9 15
Calcium carbonate 9 15
Glibenclamide 5 8.3
Others 4 6.7
Blood and hematopoietic organs (B) 1 0.44
Clopidogrel 1 1.6
Cardiovascular system (C) 99 44.2
Simvastatin 24 40
Captopril 15 25
Hydrochlorothiazide 12 20
Enalapril 10 16.6
Metoprolol 9 15
Doxazosin 8 13.3
Others 21 35
Systemic hormones (H) 3 1.34
Levothyroxine 3 5
Musculoskeletal system (M) 2 0.9
Nimesulide 1 1.6
Piroxicam 1 1.6
Central Nervous System (N) 18 8.03
Citalopram 5 8.3
Bromazepam 3 5
Paracetamol 2 3.3
Alprazolam 1 1.6
Others 7 11.67
Considering the Table 4, there were two serious drug 
interactions and five moderate interactions involving 
omeprazole. Of the drugs most involved in interactions, 
we can highlight citalopram (8.4%), Ginkgo biloba (6.7%) 
and levothyroxine (5%).
Table 4 - Medications interacting with omeprazole, 
measure of severity and outcome of the drug interaction 
in elderly people under chronic use of omeprazole from 
the public system in Panambi city, Rio Grande do Sul 
State. n=60. 2016. 
Medicines that 
interact with 
omeprazole
Interaction 
severity
Interaction outcome n %
Citalopram Serious
Increased exposure of 
citalopram and risk of 
QT prolongation
5 8.4
Ginkgo biloba Moderate
The effectiveness of 
omeprazole is reduced
4 6.7
Levothyroxine Moderate Increased TSH levels 3 5
Clopidogrel Serious
Reduced efficacy 
of clopidogrel and 
increased risk of 
thrombosis
1 1.7
Carbamazepine Moderate
Increased risk of toxicity 
of the carbamazepine
1 1.7
Propranolol Moderate
Increased exposure of 
propranolol
1 1.7
Alprazolam Moderate
Toxicity, CNS 
depression, ataxia, 
lethargy
1 1.7
Bearing in mind the drugs that have their absorption 
altered by the concomitant intake of omeprazole due to 
the gastric alteration, we can mention those present in the 
cardiovascular system, with predominance of captopril 
(25%), enalapril (16.7%) and acetylsalicylic acid (15%), 
as can be seen in Table 5.
Table 5 - Medications with the description of their pKa and 
physiological changes occasioned by the drug associated 
use in patients under chronic use of omeprazole from the 
public system in Panambi city, Rio Grande do Sul State. 
n=60. 2016. 
Medicines 
with altered 
absorption 
Drug pKa Alteration n %
Cardiovascular
Captopril 3.7
Decreases 
antihypertensive effect
15 25
Enalapril 3.0 – 5.4
Decreases 
antihypertensive effect
10 16.7
Acetylsalicylic 
acid
3.5
Decreases platelet 
antiaggregant effect
9 15
Doxazosin 6.93 Increases urinary flow 8 13.4
Losartan 4.1
Decreases 
antihypertensive effect
8 13.3
Ciprofibrate 4.6 Increases cholesterol 2 3.4
Gastrointestinal tract/metabolic
Glibenclamide 6.5
Increases blood 
glucose
5 8.4
Calcium 
carbonate
 A A 9 15
Hormonal
Levothyroxine 2.2 – 6.5 – 10.1
Decreases thyroid 
hormone replacement
3 5
Others  - 8 13.3
Note: A– does not have pKa.
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DISCUSSION
Herein, slightly more than half of the chronic users 
of omeprazole are women with an average age above 65 
years old. Similar data were found in another study16 with 
349 adult omeprazole patients, the majority of whom were 
female, elderly and with an average age of 64.4 years old. 
Other studies with PPIs found similar results to this study 
with regards to both age and gender.6,17,18,19 Most of the 
interviewees reside with relatives and one study identified 
that the elderly living alone are three times more likely 
to fail to adhere to pharmacological treatment and lack 
of companionship is associated with memory loss, which 
favors the forgetting of medication administration, which 
is a factor for irrational use and culminating in serious 
adverse events.20
The most prevalent comorbidity among the interviewees 
was SAH. This is the most frequent chronic disease in 
clinical practice among the elderly, and is characterized 
as a multifactorial and late detection problem due to its 
asymptomatic course and is considered the main risk 
factor for cardiovascular morbidity and mortality, and 
this risk increases with age.21 Dyslipidemia was also cited 
by the interviewees, and the elderly have a high prevalence 
of this comorbidity, and their control is necessary since 
approximately 75% of this population presents subclinical 
atherosclerotic disorders.22
Concerning the most self-reported purposes of 
use by the elderly people, it was found that most used 
omeprazole for gastritis, followed by heartburn and reflux 
esophagitis. And yet, a large part claimed to have dyspeptic 
symptoms. According to the NTF, omeprazole is indicated 
for symptomatic gastroesophageal reflux disease, reflux 
esophagitis, hypersecretory conditions, peptic ulcers of 
multiple etiologies, and as an adjuvant in the treatment 
of Helicobacter pylori infections.8 In one study, high use 
of omeprazole in omeprazole patients hospitalized with 
gastritis.23 This drug is used to control gastric acidity and 
treat peptic ulcers and esophageal reflux disease.5 As for 
dyspeptic symptoms, one study found that omeprazole was 
the most prescribed drug for the treatment of dyspepsia.24 
And another study adds that PPIs are promising in the 
treatment of dyspeptic symptoms and dyspepsia.25
No patient reported having Helicobacter pylori. 
Nonetheless, this bacterium is considered to be the main 
cause of chronic gastritis and its identification is performed 
through biopsy examination by digestive endoscopy, and 
the standard treatment for this infection is the combination 
of the use of two antibiotics, amoxicillin and clarithromycin, 
with an PPI such as omeprazole.5 In one study, of the 
150 patients followed up with complaints compatible with 
peptic diseases, 98 patients presented a positive result 
for Helicobacter pylori.26 A systematic review published 
in Cochrane has assessed the combination of empirical 
therapy and research procedures initial in patients with 
heartburn and epigastric pain and it was found that PPIs 
were significantly more effective than H2 antagonists and 
antacids in reducing the recurrence of symptoms. The 
same author points out that the initial endoscopy and the 
test for Helicobacter pylori lead to the reduction of the 
risk of recurrence of problems related to gastric acidity 
in comparison to the treatment without proving, thus, 
the strategy of testing Helicobacter pylori and treating it 
exceeds the suppression acidity.27
It is believed that many patients are unaware that 
they present this bacterium, as well as its diagnosis and 
treatment. The same happens with the use of antimicrobials 
for Helicobacter pylori, as already described, that many 
patients use without the accomplishment of an antibiogram 
to identify the aggressor microorganism and its sensitivity. 
The need for a complete investigation of the problem 
concomitant to the initiation of pharmacological treatment 
is emphasized since the non-identification of the pathogen 
can mask the diagnosis, cause serious toxicity, and select 
resistant microorganisms.28
According to Table 2, most interviewees use doses of 
20 mg a day. According to Micromedex13 the daily dose of 
20 mg is recommended for most indications of omeprazole 
use as active duodenal ulcer, gastroesophageal reflux 
disease, reflux esophagitis, treatment of NSAID-induced 
ulcers, gastric ulcer infection of the gastrointestinal tract 
by Helicobacter pylori, among others. Some interviewees 
use a dose higher than 20 mg/day and the most frequent 
justification for the use of this dose was gastritis, yet, in a 
data collection study, reflux disease was the most described 
justification for the use of the dose above of 20 mg/day.16 
Still according to Micromedex,13 in cases of duodenal ulcer 
disease caused by Helicobacter pylori, hypersecretory 
gastritis, and active gastric ulcer, it is recommended to 
use 40 mg or more for a specific time. The appropriate 
one would be to evaluate the dose and to correlate with 
the therapeutic indication, but in this study the indication 
was self-reported, being a limitation of the same.
Observing the omeprazole treatment time, half of the 
participants have been using for less than 5 years according 
to Table 2. Few interviewees use calcium concurrently with 
omeprazole. The use of omeprazole for long periods can 
significantly reduce bone mineral density, since elevated 
gastric pH interferes with the absorption of calcium.9 In 
the sources studied, no information was found on pKa 
for calcium carbonate.29,30
The association of prolonged use of omeprazole 
with the aging process, which decreases the rate of bone 
remodeling, allows the occurrence of microfractures that, 
when accumulating, compromise the bone,31 influences 
the recurrence of problems related to falls in elderly 
people. The occurrence of falls in the elderly is related to 
the duration of use and the dose of PPI.32 The PPIs can 
lead to an increase in the risk of spinal, wrist and total 
fractures in postmenopausal women.8 Consequently, it 
is very important the correct indication for use of this 
medication with periods established by the prescribers,33 
as well as monitoring its use by the professionals.
The most frequently cited shift was in the morning. 
PPIs should be administered 30 to 60 minutes before 
breakfast or the first substantial meal of the day. This 
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schedule not only increases absorption but also allows 
a high level of drug to reach the parietal cells when the 
proton pumps are ready to be activated.34 This data 
demonstrates that the participants in the present study 
are using properly, time of administration, omeprazole 
ensuring maximum absorption.
Few elderly have reported side effects with omeprazole, 
the most frequent complaint about headaches. In one study 
of 46 elderly omeprazole users, only one had diarrhea as an 
adverse reaction to the drug.35 A literature review pointed to 
the low frequency of adverse effects in prolonged treatment 
with PPI.36 It is noteworthy that adverse reactions are more 
frequent at baseline of the treatment and for this study, 
only the elderly who used omeprazole for six months or 
more were considered. Nevertheless, safety and lack of 
toxicity in the long term still require further studies.
Side effects may be more frequent with the use of 
associated medications. In the present research, some 
elderly people use other drugs for the stomach. According 
to NTF, PPIs, when administered alone, have a definite 
efficacy in reducing symptoms and accelerating the healing 
of ulcers, gastric or duodenal and being considered more 
effective than H2 antagonists. Nonetheless, the same form 
advises that its use is not for the purpose of immediately 
relieving the epigastric burning, since the complete effect 
occurs after 1 to 4 days of treatment, therefore, antacids can 
be administered concomitantly to relieve stomach acid.8
Regarding the pharmacological compliance, the majority 
reported using omeprazole daily, the few who reported 
forgetting to administer the medications stated that when 
they forget they no longer use that day. In one study 81.4% 
of the elderly PPI users reported forgetting to administer 
antiulcer drugs frequently.17 The lack of compliance to 
medical prescription affects unnecessary costs and impairs 
the patient’s response to the proposed treatment.37
The compliance may also be related to access to the 
drug, although omeprazole is being made available by the 
public pharmacy of the municipality under scrutiny. In 
the municipality of Serafina Correia/RS, this medicine is 
also dispensed free of charge by the city’s basic pharmacy 
and it was verified that omeprazole in 2014 was the most 
widely used drug.38 When this drug is missing in the basic 
health network, most interviewees reported purchasing it 
from commercial pharmacies. It is worth noting that the 
lack of medication in public health units mainly affects 
the most vulnerable, the lower income individuals, who 
generally depend on the free acquisition of medication as 
the only treatment alternative.39 In the present study, the 
majority of elderly users of omeprazole does not remain 
without the drug and this directly reflects on the therapeutic 
observance and consequently, on the improvement of the 
symptoms related to the purposes of use.
Some elderly chronic users of omeprazole also take 5 or 
more medications concomitantly. The use of five or more 
drugs in the therapy is considered polypharmacy and its 
use is frequent in the elderly due to chronic diseases and 
can generate the indiscriminate use of drugs, contributing 
to the drug interactions.40 In a study with the elderly, it was 
verified that 42% of these were polypharmacy,19 and yet 
another study observed at the time of the hospitalization 
of the elderly in the Santa Casa da Misericórdia Hospital in 
Vitória/ES that 40.6% of them used more than 5 medicines.41 
The elderly population is more exposed to the related risks 
to drugs because they present physiological changes in the 
body that significantly affect both the pharmacokinetics 
and pharmacodynamics of most drugs, triggering either 
increased drug toxicity or adverse reactions.8
Most of the interviewees in this study use drugs that 
act on the gastrointestinal tract and metabolism, followed 
by the cardiovascular system, according to Anatomical 
Therapeutic Chemical (ATC) classification, first level. The 
results obtained in the present study differ from those 
found by Lucchett (2010)42 in which 70.3% of the drugs 
used by elderly people act in the cardiovascular system, 
also in another study the drugs that act in this system 
were pointed out as being most used by this age group, 
corresponding to 35%,43 also Guimarães and Silva (2016)44 
verified that the drugs most frequently prescribed in their 
study, involving potentially inappropriate drugs among 
the elderly, acted in the cardiovascular system (29%). This 
difference of the present study with the others mentioned 
is due to the inclusion criterion of this research that was 
to make continuous use of omeprazole, and this drug, 
according to ATC classification, acts on the gastrointestinal 
tract and metabolism.
Omeprazole was the most frequent drug in this 
study, however, it was an inclusion criterion to make 
continuous use of this drug. Following this, simvastatin 
and captopril, which act in the cardiovascular system, 
are more frequently used by the interviewees. Also in the 
study lead by Mascarenhas,19 in which simvastatin was the 
second most commonly used by the elderly (38%) and 
also in the Vieira study,45 it was verified that this drug is 
part of the drug therapy of 53.1% of the elderly studied. 
One study found that captopril was among the drugs most 
commonly used by elderly people living in a long-term 
institution, then totaling 31.7%.46 Associated with the 
aging population, there is an increase in the prevalence 
of chronic-degenerative diseases associated with age, 
cardiovascular diseases.43 The drugs most frequently used 
by elderly chronic users of omeprazole are related to the 
diseases most prevalent in this study, already mentioned.
Serious drug interactions with omeprazole have been 
identified in Table 4. The most frequent interaction was 
with citalopram, which when combined with omeprazole 
increases blood levels of the selective serotonin reuptake 
inhibitor (SSRI) antidepressant and may increase the risk 
of side effects, including changes in heart rhythm.
Regarding the clopidogrel, the administration of 
omeprazole with this medicinal product decreases the 
cardioprotective effect of clopidogrel, since the route of 
metabolization of the two drugs occurs via Cytochrome 
P450 2C19. In a study of patients over 66 years old who 
began treatment with platelet antiaggregant after acute 
myocardial infarction and who were already using PPI, 
an increase in the risk of a new infarction in the short 
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term was found.47 Another study verified that patients 
with coronary angioplasty using clopidogrel and PPI had 
a lower antiplatelet response compared to patients who 
did not use antiulcer drugs.48
Another potential drug interaction observed in this study 
was between omeprazole and Ginkgo biloba. Concomitant 
administration of these agents reduces the bioavailability 
of omeprazole and increases the plasma concentration 
of its active metabolite, termed 5-hydroxypyrazole. This 
data indicates that Ginkgo biloba can induce the CYP2C19 
isoform and thereby reduce the plasma concentration of 
omeprazole,49 then reducing its therapeutic effect.
An additional problem related to the use of omeprazole 
is the change in the absorption of some drugs, according 
to Table 5. The elderly chronic users of omeprazole who 
use medicinal products in association are likely to have 
their absorption compromised due to pH change caused by 
omeprazole in the gastric treatment. The drugs that undergo 
alteration of absorption by the decrease of acidity are those 
presenting pKa between 2,5 and 7,5, as the undissociated 
proportion varies considerably depending on the pH.50
Among the medications used by the interviewees, 
which have their absorption altered by concomitant use 
with omeprazole, the ones that work in the cardiovascular 
system stand out. The reduction of the antihypertensive 
effect may lead to complications such as stroke, acute 
myocardial infarction, and chronic kidney disease, as well 
as changes in systolic and diastolic blood pressures.51 A 
study carried out with normotensive and hypertensive rats 
using omeprazole to verify the influence of gastric pH on 
the hypotensive effect of sodium nitrite. The results of this 
study suggest that omeprazole enhances the hypotensive 
effect of sodium nitrite.52 Therefore, it is emphasized 
the need for pharmaceutical follow-up to identify drug-
related problems and to ensure the efficacy and safety of 
pharmacological treatments.
Medications that act on the gastrointestinal tract and 
metabolism, like glibenclamide, also undergo changes of 
absorption due to gastric alterations caused by omeprazole. 
The change observed was an increase in blood glucose, as 
inadequate absorption of hypoglycemic drugs increases 
blood glucose levels. Thus, symptoms of hyperglycemia 
become more evident such as polyuria, polydipsia, weight 
loss, polyphagia and blurred vision or acute complications 
that can lead to diabetic ketoacidosis. Likewise, decreased 
control of hyperglycemia is associated with damage, 
dysfunction, and failure of various organs, especially the 
eyes, kidneys, nerves, heart, and blood vessels.53 The altered 
absorption of medications should be monitored by health 
professionals as they interfere directly efficacy and safety 
of the medicines used by patients taking omeprazole.
Considering the prolonged use of omeprazole, the drug 
interactions and the alterations of drug absorption caused by 
the continuous use of omeprazole, it is important to evaluate 
the practice of deprescription. This is based on a rigorous 
analysis of prescriptions to identify problems related to 
medicines used by the elderly, aiming to improve the quality 
of pharmacotherapy. Bearing in mind the aforesaid, health 
professionals, especially physicians, pharmacists, and nurses, 
may suggest therapeutic approachs to prevent the occurrence 
of drug interactions and adverse reactions.54 Hence, the 
Brazilian public health system needs to incorporate 
information about the process of deprescription aiming 
that this practice can become part of the therapeutic routine.
CONCLUSIONS
Knowing the profile of omeprazole users is important to 
ensure safety and effectiveness in the treatment of elderly 
patients. It was observed that although the majority of chronic 
users of omeprazole take this drug correctly, they continue to 
take this PPI for prolonged periods, then being susceptible to 
drug interactions and altered absorption that might decrease 
the therapeutic effects and also increase adverse events.
The lack of knowledge of elderly people with regards to 
both diagnosis and treatment, which was verified in this 
study, reinforces the need for follow-up for these patients 
with an emphasis on the deprescription and rational use of 
medications to guarantee therapeutic efficacy. Moreover, it 
shows the need for implementation of care protocols and 
pharmacotherapeutic follow-up, which can help the elderly, 
by improving the medication use and their life quality as well.
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